PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.
The Vilcek Foundation awarded the 2025 Prizes in Biomedical Science to Marianne Bronner, Elham Azizi, Guosong Hong, and Maayan Levy.
Hosted on MSN17m
Say Au Revoir to the Biofabricate Summit Paris 2025Biofabricate announced the organization will not return to Paris for its next-gen biomaterials summit this year, despite last year's success.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback